Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Ultragenyx Pharmaceutical Inc. < Previous 1 2 3 Next > Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) February 23, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update February 15, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update February 08, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA) February 06, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman Syndrome February 05, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease January 25, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) January 19, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones January 07, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH) January 04, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Announces Completion of Enrollment in Global Phase 1/2 Trial of GTX-102 in Pediatric Patients with Angelman Syndrome January 03, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 02, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) December 21, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH) December 18, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx to Participate at Investor Conferences in November November 20, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) November 17, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx to Participate in the Jefferies London Healthcare Conference November 07, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Reports Third Quarter 2023 Financial Results and Corporate Update November 02, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx to Host Conference Call for Third Quarter 2023 Financial Results and Corporate Update October 26, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares October 23, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) October 20, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants October 18, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Announces Proposed Public Offering of Common Stock October 17, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Announces Program and Pipeline Updates at Analyst Day Including Interim Data from Ongoing Studies in Osteogenesis Imperfecta (OI), Angelman Syndrome (AS) and Wilson Disease October 16, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) October 12, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI) October 09, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers MREO RARE Ultragenyx to Present Pipeline Update at Analyst Day on Monday, October 16, 2023 October 05, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) September 20, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx to Participate at Investor Conferences in September August 31, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) August 18, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE Ultragenyx Reports Second Quarter 2023 Financial Results and Corporate Update August 03, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Tickers RARE < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.